The global pharmaceutical CDMO market size was estimated at USD 94.17 billion in 2022 and it is projected to hit around USD 172.02 billion by 2032, growing at a CAGR of 6.21% during the forecast period 2023 to 2032.
Many pharmaceuticals industry are struggling with the manufacturing of drug substances, and the handling of pharmaceutical applications like manufacturing of the drug, pharmaceutical industry, keeping expenses in mind and also reducing the cost of the drug, higher need for equipment with affordable cost, to keep an eye on all these pharmaceutical industrial factors the Contract Development and manufacturing organization (CDMO) comes in partnership with the pharmaceutical industries to form innovative formulas and products into the market without investing additional expenses or infrastructure to support.
The Pharmaceutical CDMO handles the outsourcing of drug substances and works with innovation and development program that occurs before manufacturing one. The Pharmaceutical CDMO is one of the most important factors for the positive substantial growth of the healthcare industry.
The contract development and manufacturing organization works with the production, innovation, analysis, and development of the pharmaceutical industries. Hence the pharmaceutical industry doesn't have to build any other member of the team for innovation and development facilities. The Pharmaceutical CDMO provides the services such as packaging and shipment, blending, coating, analytic services, etc. CDMO works with formulation and preformation development services and commercial and clinical services. The Pharmaceutical CDMO is very essential part of the healthcare industry in terms of current market conditions.
The Increase in the population all over the world would create major healthcare opportunities in the forecast period. The ever-rising need for the pharmaceutical industry and manufacturing and development the contract development and manufacturing organization is important to manage all the innovation and development programs under one roof. The CDMO provide the pharmaceutical industries with the outsourcing of drug in lessen time and in a cost-effective manner. The increase in the investment in research and development programs from the pharmaceutical industry will result in an increase in the development of the pharmaceutical CDMO industry.
The rising investment into the research and development program on CDMO pharmaceuticals across the world will result in an increase in the market. The growing need for technological advancement in the pharmaceutical industries and drug development and production in the healthcare industry will be expected to rise up the market for Pharmaceutical CDMO.
Report Scope of the Pharmaceutical CDMO Market:
|Market Size in 2023||USD 100.02 Billion|
|Market Size by 2032||USD 172.02 Billion|
|Growth Rate from 2023 to 2032||CAGR of 6.21%|
|Forecast Period||2023 to 2032|
|Segments Covered||By Product, By Drug Product, By Dosage Form, By Indication, and By End-User|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America and Middle East & Africa|
An increase in chronic disease treatment will likely to drives the market
The contract development and manufacturing organization is work with the development and production of the drug as well as the technological advancements in the pharmaceutical industry. The increasing prevalence of chronic diseases in the population will end up on the increase in the need for advanced and effective treatment for the quick and better cure of people. The rise in chronic diseases like cancer is driving the market. Cancer causes the largest amount of death over the decades. The rising need for the advancement of treatment and increasing demand for the treatment of cancer will drive the pharmaceutical and contract development and manufacturing organization market.
Furthermore, the growth in generic medicines and personalized medicine will also have a positive impact on the contract development and manufacturing organization market. Technological advancement of the healthcare industry, finished drug formulation. Increasing collaboration among pharmaceutical industries, rising research and development investments, increase in old aged population will result in higher market growth of the pharmaceuticals CDMO market.
Lower profit share for the pharmaceutical industry
The Involvement of the outsourcing firm in the production of pharmaceutical drugs and technological advancement for the healthcare industry would result in a lower profit share for the pharmaceutical industry. The factors like raw materials, the number of purchased orders, labor force will affect the investment done by the pharmaceuticals industry. In outsourcing production like Pharmaceutical CDMO, there is an issue in visibility into the manufacturing process as compared to the in-house manufacturing process. If there are any manufacturing and production defects done by Pharmaceutical CDMO, the pharmaceuticals industry would be responsible for the problem and there is reputational damage to the firm.
Technological advancement in the CDMO
Pharmaceutical contract development and manufacturing organization (CDMO) carries innovative operational technologies. The increase in the demand for precision medicine and generics medicines will result in future growth opportunities in the contract development and manufacturing organization market. Technological advancements such as deployment of artificial intelligence, block chain, cloud computing and machine learning are expected to offer lucrative opportunities for the market’s growth during the forecast period.
The pharmaceutical CDMO is setting goals towards technology leadership and is projected to increase in the upcoming decades. The rising merger and acquisition in the contract development and manufacturing organization will expand the market growth.
The API segment held the largest market revenue in the contract development and manufacturing organization market in 2022, the segment will continue to grow at a significant rate during the forecast period. The API (Active Pharmaceutical Ingredients) is the initial form of the final drug product. The contract development and manufacturing organization made the major investment in the APIs market as there is an increase in the demand for the segment. The API is useful for the diagnosis, cure, and treatment or prevention of diseases that affect the human body. The API includes the type of drug like innovative and generic drugs.
The drug segment will increase significantly in the contract development and manufacturing organization market in the forecast period. The drug segment includes oral solid dose, semi-solid dose, liquid dose, and others. The drug type is useful for the treatment of several diseases. The growing number of chronic diseases within the population results in the growth in the drug segment.
Dosage Form Insights:
Solid Dose had the largest market size in the contract development and manufacturing organization in 2022. The demand for the solid dose segment is attributed to the longer shelf-life and the instant effect of the medicine will expand the demand for the solid dose segment in the predicted timeframe. The outsourcing of solid doses for the Pharmaceutical CDMO will be expanding due to the higher demand of the segment.
Gases Dose is significantly increasing in the contract development and manufacturing organization in the forecast period. Gases do include inhalers and aerosol. The changing environmental conditions and increase in diseases related to the lungs and intestines are expanding the market demand for the gases dose segment.
The pain indication segment is rising significantly in the contract development and manufacturing organization in the analyzed period. The rising demand for pain indication treatment demand increases the treatment of chronic pain in the human body. The demand for the pain indication segment is expanding due to the rise in the geriatric population across the globe. Outsourcing pain relief medication production will help the pharmaceutical industry to lower the cost.
The big pharmaceutical industry holds the largest market segment in the contract development and manufacturing organization market in 2022. The big pharmaceutical industries had the bulk of investment in the Pharmaceutical CDMO market and can invest in drug development and production. Outsourcing and manufacturing of drugs to CDMO will reduce the cost of the drug and help the big pharmaceutical industry to compete in the market.
The small and medium-scale pharmaceutical industry will show steady growth in the contract development and manufacturing organization in the analyzed period. Lack of capital and potential to invest in advanced facilities hamper the growth of small-scale pharmaceutical companies.
Asia-Pacific holds the largest market share of the contract development of manufacturing organizations in the anticipated timeframe, the region is expected to grow at a significant rate during the forecast period. The growth of pharmaceutical CDMO market in the region is attributed to the increasing population in the countries such as India and China. The rising population in this region results in an increased demand for advanced and reliable medical facilities. The development of a contract development and manufacturing organization market in the Asia-Pacific region is due to the lower cost of the manufacturing industries, lower labor cost, and beneficial government regulations. The increasing demand for generic and personalized medicines in these regions will support in continuing the dominance of the Asia-Pacific region in the Pharmaceutical CDMO market.
North America is another largest marketplace for pharmaceutical CDMO services. The region is expected the boost due to the expansion of manufacturing units of pharmaceutical industries. The rise in the geriatric population in this region would result in a higher demand for such services form the healthcare industry. Growing technological innovation in the pharmaceutical industry will propel contract development and manufacturing organization market growth. Moreover, the well-established healthcare infrastructure along with favorable government policies in improving healthcare services supplements the growth of the market in North America.
Europe is expected to witness a noticeable growth in the pharmaceutical CDMO market during the forecast period. Countries including France, United Kingdom and Germany are expected to be the largest contributors for the growth of the market in Europe. The region is expected to grow with the rising investment in the pharmaceutical sector for a better healthcare system.
Key Market Players:
Segments Covered in the Report:
(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)
By Drug Product
By Dosage Form
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client